Wipro GE Healthcare has announced an investment of over Rs 8000 crore in manufacturing output & local R&D over next 5 years. This strategic investment bolsters Wipro GE Healthcare’s local manufacturing footprint to address the growing domestic and international market and will build supply chain resiliency for the organisation. 

As a part of this investment, the Wipro GE Healthcare ‘Made in India’ PET CT Discovery IQ will be exported to 15 countries. Additionally, the ‘Made in India’ Revolution Aspire CT, Revolution ACT and MR breast coils will be manufactured ‘In India for the World’. 

Over the decades, the organisation has fostered a strong local supplier ecosystem of medtech component manufacturing, covering capabilities like plastics, EMS, machining, castings, 3D printing, contributing $1 million supplier labour hours. The investment will include creation of additional 400,000 labour hours.

Currently, the organisation has four manufacturing plants in Bengaluru. All four manufacturing plants are export plants, the latest one established in March 2022 with an investment of a little over Rs 100 crore under the Indian government’s PLI Scheme.